7 completed, 3 terminated, 2 withdrawn, 1 recruiting. 13 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Completed 7, Terminated 3, Withdrawn 2, Recruiting 1 |
Follow Short Bowel Syndrome: new trials by email Literature Review of Short Bowel Syndrome trials Research Report on Short Bowel Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase IV Study of rhGH Injection in Adult Short Bowel Syndrome rhGH injection - Short Bowel Syndrome (SBS) in Adults | Phase 4 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 100 | 2024-07-31 | 2026-07-08 |
| Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A) Clinolipid, Intralipid - Essential Fatty Acid Deficiency (EFAD) | Phase 4 | Completed | Baxter Healthcare Corporation | 101 | 2021-01-22 | 2023-12-27 |
| Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition Apixaban single dose, Apixaban steady-state - Short Bowel Syndrome, Anticoagulation | Phase 4 | Completed | Universitaire Ziekenhuizen KU Leuven | 70 | 2020-12-20 | 2026-10-15 |
| Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients Teduglutide - Short Bowel Syndrome | Phase 4 | Completed | Assistance Publique - Hôpitaux de Paris | 25 | 2018-07-02 | 2025-09-11 |
| SMOFLipid in Patients Who Are Intralipid Intolerant SMOFLipid, Standard therapy - Home Parenteral Nutrition, Short Bowel Syndrome | Phase 4 | Withdrawn | Mayo Clinic | 2017-02-01 | 2018-03-22 | |
| The Use of DPP-4 Inhibitors in Short Bowel Syndrome Dipeptidyl peptidase-4 inhibitor - Short Bowel Syndrome | Phase 4 | Terminated | Stanley Dudrick's Memorial Hospital | 8 | 2016-01-01 | 2020-04-15 |
| Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion Clinolipid, Intralipid - Essential Fatty Acid Deficiency (EFAD) | Phase 4 | Terminated | Baxter Healthcare Corporation | 1 | 2015-05-01 | 2021-07-21 |
| rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome rtPA lock therapy - Short Bowel Syndrome | Phase 4 | Completed | Lynn Malec | 8 | 2015-02-01 | 2018-02-06 |
| Short Bowel Syndrome and Teduglutide Versus Placebo Teduglutide, Placebo - Short Bowel Syndrome | Phase 4 | Completed | Mayo Clinic | 8 | 2014-01-01 | 2016-02-22 |
| Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome Exenatide, Placebo - Short Bowel Syndrome | Phase 4 | Withdrawn | Mayo Clinic | 2013-03-01 | 2014-01-14 | |
| The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Short Bowel Syndrome Patients ursodeoxycholic acid - Short Bowel Syndrome | Phase 4 | Completed | Jinling Hospital, China | 30 | 2013-01-01 | 2017-02-24 |
| rHGH and Intestinal Permeability in Intestinal Failure Somatropin, Seven Day Food Diary, Blood Tests (standard of care) - Short Bowel Syndrome | Phase 4 | Completed | Northwestern University | 15 | 2006-10-01 | 2016-02-08 |
| Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS) Growth Hormone - Short Bowel Syndrome | Phase 4 | Terminated | University of Nebraska | 5 | 2003-09-01 | 2023-09-08 |
Hyperphagia (4) · Pena Shokeir syndrome, type 1 (2) · Intestinal Failure (1) · Malabsorption Syndromes (1)
Digestive System Diseases (13) · Gastrointestinal Diseases (13) · Intestinal Diseases (13) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Postoperative Complications (13) · Malabsorption Syndromes (12) · Signs and Symptoms (4) · Signs and Symptoms, Digestive (4) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1)
Growth Hormone (2) · Standard of Care (2) · soybean oil, phospholipid emulsion (2) · teduglutide (2) · ALX-0600 (1) · Angptl4 protein, mouse (1) · Diet Records (1) · Dipeptidyl-Peptidase IV Inhibitors (1) · Exenatide (1) · Hematologic Tests (1) · Human Growth Hormone (1) · SMOFlipid (1) · Sitagliptin Phosphate (1) · Urine Specimen Collection (1) · Ursodeoxycholic Acid (1)
Mayo Clinic (3) · Baxter Healthcare Corporation (2) · Assistance Publique - Hôpitaux de Paris (1) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Jinling Hospital, China (1) · Lynn Malec (1) · Northwestern University (1) · Stanley Dudrick's Memorial Hospital (1) · Universitaire Ziekenhuizen KU Leuven (1) · University of Nebraska (1)
United States (7) · China (2) · Belgium (1) · France (1) · Poland (1)
Michael Camilleri, MD (2) · Fedja Rochling, MB, ChB (1) · Jonathan Fryer, MD (1) · Lynn Malec, MD (1) · Manpreet S Mundi (1) · Wencheng Kong, MD (1)
PMID 26223941, PMID 37270289, PMID 40415417
2017 (1), UL1TR000135 (1)